Assoc. Prof. GÜLDANE CENGİZ SEVAL

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation , vol.22, no.5, pp.373-380, 2024 (SCI-Expanded)

43. Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri

KOYUN D., YÜKSEL S., Cengiz Seval G., CİVRİZ BOZDAĞ S., Toprak S. K., Topcuoglu P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.8, no.1, pp.39-45, 2024 (TRDizin)

44. Safety of ovarian cryopreservation and transplantation in patients with acute leukemia: a case series

SÖNMEZER M., ŞÜKÜR Y. E., Saçıntı K. G., Özkavukçu S., ENNELİ D., ATABEKOĞLU C. S., et al.

American Journal of Obstetrics and Gynecology , vol.230, no.1, 2024 (SCI-Expanded, Scopus)

45. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

Musto P., Salmanton-García J., Sgherza N., Bergantim R., Farina F., Glenthøj A., et al.

Hematological Oncology , vol.42, no.1, 2024 (SCI-Expanded, Scopus)

46. Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)

Kastritis E., Katodritou E., Badelita S., Bila J., CENGİZ SEVAL G., Cvetkovic Z., et al.

LEUKEMIA & LYMPHOMA , vol.65, no.13, pp.2064-2067, 2024 (SCI-Expanded, Scopus)

47. The world apheresis association registry, 2023 update

Vrielink H., Le Poole K., Stegmayr B., Kielstein J., Berlin G., Ilhan O., et al.

Transfusion and Apheresis Science , vol.62, no.6, 2023 (SCI-Expanded, Scopus)

48. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings.

Rossi G., Salmanton-García J., Cattaneo C., Marchesi F., Dávila-Valls J., Martín-Pérez S., et al.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases , vol.137, pp.98-110, 2023 (SCI-Expanded, Scopus)

49. Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis

Çubukçu H. C., Mesutoğlu P. Y., Seval G., Beksaç M.

CLINICAL AND EXPERIMENTAL MEDICINE , vol.23, no.6, pp.2503-2533, 2023 (SCI-Expanded, Scopus)

50. Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma

CENGİZ SEVAL G., DALVA K., Bakanay S. M., Soydan E., İLHAN O., BEKSAÇ M., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023 (SCI-Expanded, Scopus)

51. Validation of two international myeloma staging systems: second revision of ISS and mayo additive staging sytems (MASS) in an external cohort of Ankara University

CENGİZ SEVAL G., Aydogan M., Akbulut M. H., KARAKAYA B., Yavuz G., YİLMAZ H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023 (SCI-Expanded, Scopus)

52. Bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation single center experience

IŞIK Ö., CENGİZ SEVAL G., EROL S., GÜRÜN KAYA A., TOPRAK S. K., ÖZDEMİR KUMBASAR Ö.

EUROPEAN RESPIRATORY JOURNAL , 2023 (SCI-Expanded, Scopus)

53. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

CENGİZ SEVAL G., Civriz Bozdag S., TOPRAK S. K., Kurt Yuksel M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Balkan medical journal , vol.40, no.3, pp.197-204, 2023 (SCI-Expanded, Scopus, TRDizin)

54. A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

BEKSAÇ M., Akin H. Y., CENGİZ SEVAL G., Yurdakul Mesutoglu P., Anliacik R. G., Anliacik E., et al.

Clinical Lymphoma, Myeloma and Leukemia , vol.23, no.5, pp.394, 2023 (SCI-Expanded, Scopus)

55. Evaluation of the Efficacy and Safety Immunosuppressive Therapy in Patients with Acquired Factor VIII and IX Inhibitor

Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Topçuoğlu P.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.76, no.1, pp.24-29, 2023 (TRDizin)

56. Evaluation of the Efficacy and Safety Immunosuppressive Therapy in Patients with Acquired Factor VIII and IX Inhibitor

KOYUN D., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., ÖZCAN M., TOPÇUOĞLU P.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.76, 2023 (Peer-Reviewed Journal)

57. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.

BEKSAÇ M., Seval G., KOYUN D., TOPÇUOĞLU P., YÜKSEL M., GÜRMAN G., et al.

Clinical lymphoma, myeloma & leukemia , vol.23, no.3, 2023 (SCI-Expanded, Scopus)

58. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.

Busca A., Salmanton-García J., Marchesi F., Farina F., Seval G., Van Doesum J., et al.

Frontiers in immunology , vol.14, pp.1125030, 2023 (SCI-Expanded, Scopus)

59. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Kırcalı E., Cengiz Seval G., Öztürk C., Yılmaz H., Koyun D., Civriz Bozdağ S., et al.

BALKAN MEDICAL JOURNAL , vol.40, no.1, pp.51-56, 2023 (SCI-Expanded, Scopus, TRDizin)

60. SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA

Dytfeld D., Radocha J., Hajek R., CENGİZ SEVAL G., Berkac M., Coriu D., et al.

Acta Haematologica Polonica , vol.54, no.2, pp.82-85, 2023 (Scopus)

61. The Many Faces of Multiple Myeloma

Bol A. T., Cengiz Seval G., Beksaç M., Kuzu I.

TURKISH JOURNAL OF HEMATOLOGY , no.1, pp.41-42, 2023 (SCI-Expanded, Scopus, TRDizin)

62. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Infante M. S., Salmanton-Garcia J., Fernandez-Cruz A., Marchesi F., Jaksic O., Weinbergerova B., et al.

FRONTIERS IN ONCOLOGY , vol.12, 2022 (SCI-Expanded, Scopus)

63. Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation- risk factors, prognosis

Isik O., CENGİZ SEVAL G., Erol S., TOPRAK S. K., ÖZDEMİR KUMBASAR Ö.

EUROPEAN RESPIRATORY JOURNAL , 2022 (SCI-Expanded, Scopus)

64. Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.8, pp.596-600, 2022 (SCI-Expanded, Scopus) Sustainable Development

65. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Lamure S., Salmanton-Garcia J., Robin-Marieton E., Jaksic O., Kohn M., Marchesi F., et al.

BLOOD ADVANCES , vol.6, no.13, pp.3870-3874, 2022 (SCI-Expanded, Scopus)

66. Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease

KOYUN D., CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.3, pp.601-605, 2022 (SCI-Expanded, Scopus)

67. İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., ŞENOYMAK M. C., YAVUZ G., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.6, no.2, pp.50-55, 2022 (TRDizin)

68. Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association

Joris M. M., Schmidt A. H., Bernas S. N., Feinberg J., Sacchi N., Elmoazzen H., et al.

BONE MARROW TRANSPLANTATION , vol.57, no.6, pp.1021-1024, 2022 (SCI-Expanded, Scopus)

69. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome

CENGİZ SEVAL G., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAY B. N., et al.

Dermatologic Therapy , vol.35, no.5, 2022 (SCI-Expanded, Scopus)

70. A case report of an atypical FIP1L1-PDGFRA fusion in a patient with hypereosinophilia

EKİNCİ S., CENGİZ SEVAL G., KARABULUT H. G., Vicdan A., YÜKSEL S., KUZU I., et al.

EUROPEAN JOURNAL OF HUMAN GENETICS , vol.30, no.SUPPL 1, pp.222, 2022 (SCI-Expanded, Scopus)

71. SARS-CoV-2 Mutations and their Viral Variants

Cosar B., Karagulleoglu Z. Y., Unal S., Ince A. T., Uncuoglu D. B., Tuncer G., et al.

CYTOKINE & GROWTH FACTOR REVIEWS , vol.63, pp.10-22, 2022 (SCI-Expanded, Scopus)

72. Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?

CENGİZ SEVAL G., BEKSAÇ M.

FRONTIERS IN ONCOLOGY , vol.12, 2022 (SCI-Expanded, Scopus)

73. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Civriz Bozdağ S., Cengiz Seval G., Yönal Hindilerden İ., Hindilerden F., Andıç N., Baydar M., et al.

TURKISH JOURNAL OF HEMATOLOGY , vol.39, no.1, pp.43-54, 2022 (SCI-Expanded, Scopus, TRDizin)

74. Evaluation of the distribution and antimicrobial susceptibility of gram-negative bacteria isolated from blood cultures in heamatologic febrile neutropenia attacks

ÇINAR G., ÖCAL D., CENGİZ SEVAL G., AKDEMİR KALKAN İ., GÜLTEN E., SARICAOĞLU E. M., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.3, pp.373-378, 2022 (TRDizin)

75. A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

BEKSAÇ M., Akin H. Y., Gencer-Oncul E. B., Yousefzadeh M., CENGİZ SEVAL G., GÜLTEN E., et al.

Immunogenetics , vol.73, no.6, pp.449-458, 2021 (SCI-Expanded, Scopus)

76. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Ilhan O., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

BLOOD , vol.138, 2021 (SCI-Expanded, Scopus)

77. Comparison of Salvage Autologous Hematopoietic Cell Transplantation with Outcomes Following Selinexor Combinations Among Double/Triple Refractory Myeloma Patients

Cengiz G., Karakaya B., Yilmaz H., Koyun D., Kircali E., Basboga S., et al.

BLOOD , vol.138, 2021 (SCI-Expanded, Scopus)

78. Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

Soto-Perez-de-Celis E., Martínez-Peromingo J., Chávarri-Guerra Y., Loh K. P., Demichelis-Gómez R., Rodrigues M., et al.

The Lancet Healthy Longevity , vol.2, no.11, 2021 (ESCI, Scopus)

79. Post-Induction Undetectable Minimal Residual Disease at 10 (-5) Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Seval G., DALVA K., Oz D., Bakanay S. M., Soydan E., GÜRMAN G., et al.

BLOOD , vol.138, 2021 (SCI-Expanded, Scopus)

80. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Pagano L., Salmanton-Garcia J., Marchesi F., Busca A., Corradini P., Hoenigl M., et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY , vol.14, no.1, 2021 (SCI-Expanded, Scopus)

81. Analysis of extracorporeal photopheresis within the frame of the WAA register

Blaha M., Berlin G., Audzijoniene J., Griskevicius A., Dykes J., Bhuiyanova Z., et al.

Transfusion and Apheresis Science , vol.60, no.5, 2021 (SCI-Expanded, Scopus)

82. The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation

CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., YÜKSEL M., DALVA K., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.74, no.3, pp.337-342, 2021 (TRDizin)

83. Relaps Refrakter Hodgkin Lenfomada Brentuksimab Vedotin Kullanımı: Tek Merkez Deneyimi

Koyun D., Cengiz Seval G., Sökmen M., Akkuş E., Atilla E., Civriz Bozdağ S., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.1, pp.1-4, 2021 (TRDizin)

84. Rosai-Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and low-dose thalidomide therapy

Kalay Yildizhan İ., ŞANLI H., AKAY B. N., Erol H. M., KUZU I., Kirmizi A., et al.

DERMATOLOGIC THERAPY , no.4, 2021 (SCI-Expanded, Scopus) Sustainable Development

85. Deleterious reproductive effects of nilotinib in mouse model

ÖZKAVUKCU İ. S., KUŞCU N., ADIGÜZEL D., CENGİZ SEVAL G., ÇELİK ÖZENCİ Ç.

REPRODUCTION , vol.161, no.3, pp.295-306, 2021 (SCI-Expanded, Scopus)

86. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

Uslu A., CENGİZ SEVAL G., Merter M., DALVA K., BEKSAÇ M.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, no.3, 2021 (SCI-Expanded, Scopus)

87. A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT

Özkan E., Araz M., Cengiz Seval G., Nak D., Beksaç M.

TURKISH JOURNAL OF HEMATOLOGY , vol.38, no.1, pp.69-71, 2021 (SCI-Expanded, Scopus, TRDizin)

88. Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy

Ozdemir Z. N., CENGİZ SEVAL G., Sahin U., Uslu A., Gunduz M., CİVRİZ BOZDAĞ S., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.37, no.1, pp.67-75, 2021 (SCI-Expanded, Scopus) Sustainable Development

89. Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic

CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.6, pp.2799-2809, 2021 (SCI-Expanded, Scopus, TRDizin)

90. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors

Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., et al.

TURKISH JOURNAL OF HEMATOLOGY , vol.38, no.2, pp.111-118, 2021 (SCI-Expanded, Scopus, TRDizin)

91. Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

Yilmaz F., SOYER N., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ÜNAL A., et al.

TURKISH JOURNAL OF HEMATOLOGY , vol.38, no.3, pp.195-203, 2021 (SCI-Expanded, Scopus, TRDizin)

92. Host variations in SARS-CoV-2 infection

Altiok D., Savci E. Z., Ozkara B., Alkan K., Namdar D. S., Tuncer G., et al.

TURKISH JOURNAL OF BIOLOGY , vol.45, no.4, pp.404-424, 2021 (SCI-Expanded, Scopus, TRDizin)

93. Allogeneic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Single Center Experience

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YİLMAZ H., GÜL YAVUZ E., KARAKAYA B., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.1, pp.16-20, 2021 (TRDizin)

94. First Turkey Experience of 11C-Methionine PET in Multiple Myeloma. D

Özkan E., Cengiz Seval G., Araz M., Küçük N. Ö., Beksaç M.

TURKISH JOURNAL OF HAEMATOLOGY , pp.1-3, 2020 (SCI-Expanded, Scopus, TRDizin)

95. Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag

Kircali E., CENGİZ SEVAL G., KOYUN D., Ozturk C., Uslu A., CİVRİZ BOZDAĞ S., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.410-411, 2020 (SCI-Expanded, Scopus)

96. Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.192-193, 2020 (SCI-Expanded, Scopus)

97. A New Hope in the Treatment of steroid-refractory Graft Versus Host Disease (Sr-GVHD) after Allogeneic Hematopoetic Stem Cell Transplantation (AHSCT): Ruxolitinib

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., Deveci B., PEHLİVAN M., Kaynar L., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.329-330, 2020 (SCI-Expanded, Scopus)

98. The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.204, 2020 (SCI-Expanded, Scopus)

99. Relapse of Immune Thrombocytopenic Purpura in a Patient With COVID-19

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., AKDEMİR KALKAN İ., TOPRAK S. K., TOPÇUOĞLU P., AZAP A., et al.

Infectious Diseases and Clinical Microbiology , vol.2, no.3, pp.184-186, 2020 (TRDizin) Sustainable Development

100. Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?

CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.305-306, 2020 (SCI-Expanded, Scopus)

101. CD34+Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

Kucukgode G. E., Ipek S., Yildirim Y., Gozukara M. G., DALVA K., CENGİZ SEVAL G., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.688-689, 2020 (SCI-Expanded, Scopus)

102. Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

Kircali E., Cengiz G., Çolak S., Gunduz M., Ataca Atilla P., Atilla E., et al.

BLOOD , vol.136, no.Supplement 1, pp.13-14, 2020 (SCI-Expanded, Scopus)

103. Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis

SEVAL G. C., ATİLLA E., ATİLLA P., BOZDAĞ S. C., YÜKSEL M., TOÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.4, no.2, pp.23-27, 2020 (TRDizin)

104. Our Approach in Allogeneic Stem CellTransplantation: 11 Years of Experience

Kırcalı E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.4, no.3, pp.50-54, 2020 (TRDizin)

105. Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis

CENGİZ SEVAL G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.4, no.2, pp.23-27, 2020 (TRDizin)

106. Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis

CENGİZ SEVAL G., ATİLLA E., ATACA A. P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.4, no.2, pp.23-27, 2020 (TRDizin)

107. Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.

Toprak S. K., Cengiz Seval G., Atilla E., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15_suppl, pp.20038, 2020 (SCI-Expanded, Scopus)

108. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Demirer T., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15_suppl, pp.19522, 2020 (SCI-Expanded, Scopus)

109. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm.

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kırcalı E., Ozturk C., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15_suppl, pp.19536, 2020 (SCI-Expanded, Scopus)

110. The Outcomes of Splenectomy and Drug Therapy in Patients with Splenic Marginal Zone Lymphoma

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., KUZU I.

LLM Dergi , vol.4, no.1, pp.10-13, 2020 (TRDizin)

111. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

BEKSAÇ M., CENGİZ SEVAL G., Kanellias N., Coriu D., Rosinol L., Ozet G., et al.

HAEMATOLOGICA , vol.105, no.1, pp.201-208, 2020 (SCI-Expanded, Scopus)

112. MİKOZİS FUNGOİDES VE SEZARY SENDROMU TANILI HASTALARIN TEDAVİSİNDE HEMATOPOİETİK KÖK HÜCRE NAKLİ SONUÇLARI:7 YILLIK MERKEZ DENEYİMİ

CENGİZ SEVAL G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.4, no.2, pp.23-27, 2020 (TRDizin)

113. First Experience of C-11-Methionine PET in Multiple Myeloma in Turkey

Ozkan E., Cengiz Seval G., Araz M., Kucuk N. Ö., Beksaç M.

TURKISH JOURNAL OF HEMATOLOGY , vol.39, no.1, pp.66-67, 2020 (SCI-Expanded, Scopus, TRDizin)

114. The natural course of non-alcoholic fatty liver disease

Cengiz Seval G., Kabaçam G., Yakut M., Seven G., Savaş B., Elhan A. H., et al.

Hepatology Forum , vol.1, no.1, pp.20-24, 2020 (ESCI, TRDizin)

115. Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Cengiz Seval G., Karaman Z., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.3, no.3, pp.55-59, 2019 (TRDizin)

116. A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R)

BEKSAÇ M., CENGİZ SEVAL G., KOYUN D., TOPÇUOĞLU P., YÜKSEL M., GÜRMAN G., et al.

AMERICAN JOURNAL OF HEMATOLOGY , vol.94, 2019 (SCI-Expanded, Scopus)

117. Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10, 2019 (SCI-Expanded, Scopus)

118. Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., Tuglular T. F., ARSLAN Ö., GÖKER H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10, 2019 (SCI-Expanded, Scopus)

119. PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma

CENGİZ SEVAL G., ÖZKAN E., BEKSAÇ M.

PET CLINICS , vol.14, no.3, pp.369-382, 2019 (ESCI, Scopus)

120. A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma

CENGİZ SEVAL G., BEKSAÇ M.

EXPERT OPINION ON DRUG SAFETY , vol.18, no.7, pp.563-571, 2019 (SCI-Expanded, Scopus)

121. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Demirer T., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.15_suppl, pp.19532, 2019 (SCI-Expanded, Scopus)

122. THE EFFECT OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES PRESENTED BY HLA-CLASS II MOLECULES ON 1 ANTIGEN/ALELLE MISMATCHED UNRELATED HSCT: A SINGLE CENTER EXPERIENCE

DALVA K., CENGİZ SEVAL G., Oz D., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

HLA , vol.93, no.5, pp.368-369, 2019 (SCI-Expanded, Scopus)

123. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.15_suppl, pp.19524, 2019 (SCI-Expanded, Scopus)

124. Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation

Atilla E., Atilla P. A., CENGİZ SEVAL G., Bektas M., DEMİRER T.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.30, no.2, pp.122-131, 2019 (SCI-Expanded, Scopus, TRDizin)

125. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience

Gorgulu B., CENGİZ SEVAL G., Kendirlinan R., TOPRAK S. K., Ozcan M., BAVBEK S.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY , vol.29, no.6, pp.468-470, 2019 (SCI-Expanded, Scopus)

126. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

Topcuoglu P., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Dalva K., et al.

BLOOD , vol.132, no.Supplement 1, pp.5776, 2018 (SCI-Expanded, Scopus)

127. Primer Mediastinal Büyük BHücreli Lenfoma HastalarımızınTedavi Sonuçlarının Geriye DönükDeğerlendirilmesi

ATİLLA E., ATACA ATİLLA P., Cengiz Seval G., TOPRAK S. K., İLHAN O., ARSLAN Ö., et al.

Türkiye’de Lösemi Lenfoma Miyelom Araştırmaları , vol.2, no.3, pp.60-64, 2018 (TRDizin)

128. Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients

CENGİZ SEVAL G., Sahin D. G., Soydan E. A., Ozcelik T., Gokmen A., Gokgoz Z., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.18, 2018 (SCI-Expanded, Scopus)

129. Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.

CENGİZ SEVAL G., Bulat B., Ozel F., Tasci O., KUZU I., CİVRİZ BOZDAĞ S., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018 (SCI-Expanded, Scopus)

130. Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation

CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.

BALKAN MEDICAL JOURNAL , vol.35, no.2, pp.131-140, 2018 (SCI-Expanded, Scopus, TRDizin)

131. The safety of bortezomib for the treatment of multiple myeloma

CENGİZ SEVAL G., BEKSAÇ M.

EXPERT OPINION ON DRUG SAFETY , vol.17, no.9, pp.953-962, 2018 (SCI-Expanded, Scopus)

132. Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model

CENGİZ SEVAL G., ÖZKAVUKCU İ. S., SEVAL M. M., Ayli M.

TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.2, pp.137-142, 2017 (SCI-Expanded, Scopus, TRDizin)

133. Demir Preparatları ve Etkinlikleri

CENGİZ SEVAL G.

Türkiye Klinikleri Hematoloji Özel Sayısı , vol.10, no.3, pp.206-211, 2017 (Peer-Reviewed Journal)

134. Akut Lösemili Hastalarda Serum Sistatin C ve Prognostik önemi

CENGİZ SEVAL G., candar T., AYLI M., COŞARDERELİOĞLU SEÇER Ç., Demirtaş S., ÖZET G., et al.

Lösemi Lenfoma Myelom , 2017 (TRDizin)

135. Mikroanjiyopatik Hemolitik Anemiler

CENGİZ SEVAL G., AYLI M.

Türkiye Klinikleri Hematoloji Özel sayısı , vol.9, no.1, pp.34-43, 2016 (Peer-Reviewed Journal)

136. Xanthelasma palpebrarum: a new side effect of nilotinib

Sayin I., Ayli M., Oğuz A. K., CENGİZ SEVAL G.

BMJ Case Reports , pp.2015213511, 2016 (Scopus)

137. Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients

CENGİZ SEVAL G., ÖZCAN M.

JOURNAL OF CLINICAL MEDICINE , vol.4, no.3, pp.441-459, 2015 (SCI-Expanded, Scopus)

138. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Ayh M., ÖZCAN M., CENGİZ SEVAL G.

TURKISH JOURNAL OF HEMATOLOGY , vol.32, no.2, pp.180-183, 2015 (SCI-Expanded, Scopus, TRDizin)

139. The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model

Seval G., Ozkavukcu S., Seval M., Ayli M., Ozcan M.

BLOOD , vol.124, no.21, pp.1799, 2014 (SCI-Expanded, Scopus)

140. Blood donors and factors impacting the blood donation decision: Motives for donating blood in Turkish sample

Karacan E., CENGİZ SEVAL G., Aktan Z., Ayli M., Palabiyikoglu R.

TRANSFUSION AND APHERESIS SCIENCE , vol.49, no.3, pp.468-473, 2013 (SCI-Expanded, Scopus) Sustainable Development

141. Sirolimus based immunosuppression is associated with need for early repeat therapeutic ERCP in liver transplant patients with anastomotic biliary stricture

Tabibian J. H., Girotra M., Yeh H., Segev D. L., Gulsen M. T., Cengiz-Seval G., et al.

ANNALS OF HEPATOLOGY , vol.12, no.4, pp.395-401, 2013 (SCI-Expanded, Scopus)

142. HTK preservative solution is associated with increased biliary complications among patients receiving DCD liver transplants: A single center experience

Gulsen M. T., Girotra M., CENGİZ SEVAL G., Price J., Singh V. K., Segev D. L., et al.

ANNALS OF TRANSPLANTATION , vol.18, pp.69-75, 2013 (SCI-Expanded, Scopus)

143. Multiple Myeloma ve Böbrek Hastalığı

AYLI M., CENGİZ SEVAL G.

Türkiye Klinikleri Nefroloji Özel Sayısı , vol.6, no.3, pp.34-38, 2013 (Peer-Reviewed Journal)

144. Hipertrigliseridemiye ba¤l› akut pankreatit tedavisinde plazmaferez

Erkan G., KAYA E. K., POLAT F. B., DEĞERTEKİN M. B., ATAÇ G. K., CENGİZ SEVAL G., et al.

Endoskopi , vol.20, no.3, pp.95-96, 2012 (TRDizin)

145. Sirolimus may be associated with early recurrence of biliary obstruction in liver transplant patients undergoing endoscopic stenting of biliary strictures

Tabibian J. H., Yeh H., Singh V. K., CENGİZ SEVAL G., Cameron A. M., Gurakar A.

ANNALS OF HEPATOLOGY , vol.10, no.3, pp.270-276, 2011 (SCI-Expanded, Scopus) Sustainable Development

146. Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population

İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., et al.

JOURNAL OF MEDICAL VIROLOGY , vol.83, no.6, pp.974-980, 2011 (SCI-Expanded, Scopus) Sustainable Development

Papers Presented at Peer-Reviewed Scientific Conferences 220

1. EASIX OUTPERFORMS EBMT AND CIBMTR RISK MODELS IN PREDICTING VOD/SOS DESPITE DEFIBROTIDE USE IN ALLOGENEIC HSCT

Bektas M., Gungor A., ŞAHİN U., Yuksel M. K., TOPRAK S. K., TOPÇUOĞLU P., et al.

52nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), ELECTR NETWORK, 22 - 25 March 2026, vol.61, pp.304-305, (Summary Text)

2. ATG KULLANILAN ALLOJENİK KÖK HÜCRE NAKLİNDE DAHA YÜKSEK TRASPLANTASYON ÖNCESİ LENFOSİT SAYISI SAĞKALIM ORANININ İYİLEŞMESİYLE İLİŞKİLİDİR

KÖKCÜ G., DALVA K., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

3. TONSİL NON-HODGKİN LENFOMALARININ KLİNİK ÖZELLİKLERİ, TEDAVİYE YANIT VE PROGNOZUNUN ANALİZİ

YÜKSEL M., YURDAKUL B. E., KÖKCÜ G., BEKTAŞ M., CENGİZ SEVAL G., TOPRAK S. K., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

4. NÜKS/DİRENÇLİ AKUT MYELOİD LÖSEMİ TEDAVİSİNDE FLAG-İDA İLE KOMBİNE VENETOKLAKS KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., DALVA K., HANEDAR E., SÖNMEZ G. M., BEKTAŞ M., YÜKSEL M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

5. SPİNAL MANYETİK REZONANS GÖRÜLTÜLEMEDE ANORMAL KEMİK İLİĞİ YOĞUNLUĞUNUN HEMATOLOJİK HASTALIKLARLA İLİŞKİSİ

AYDOĞAN M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

6. SAÇLI HÜCRELİ LÖSEMİDE KLADRİBİN MONOTERAPİSİNİN UZUN DÖNEM SONUÇLARI VE NÜKSÜ ÖNGÖREN İMMÜNOFENOTİPİK BELİRTEÇLER

BEKTAŞ M., YURDAKUL B. E., DALVA K., ŞAHİN U., CENGİZ SEVAL G., TOPRAK S. K., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

7. NÜKS/DİRENÇLİ AKUT MYELOİD LÖSEMİ TEDAVİSİNDE FLAG-İDA İLE KOMBİNE VENETOKLAKS KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., DALVA K., HANEDAR E., İŞİKAN H. E., SÖNMEZ G. M., BEKTAŞ M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October 2025, (Full Text)

8. ALLOJENİK KÖK HÜCRE NAKLİ ÖNCESİ TOTAL VÜCUT IŞINLAMASINDA 12-GY VE 8-GY DOZ YOĞUNLUĞUNUN KARŞILAŞTIRILMASI: AKUT LENFOBLASTİK LÖSEMİDE ÇOK MERKEZLİ BİR ANALİZ

TAN T., KÖKCÜ G., TOPCU A. U., ÇIĞ E., CENGİZ SEVAL G., TOPRAK S. K., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October 2025, (Full Text)

9. WHO VE ICC IŞIĞINDA MPN’LERİN GENETİK ÖZELLİKLERİ VE KLİNİK KORELASYONU

SÖNMEZ G. M., LEBLEBİCİ C. B., YÜRÜR KUTLAY N., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

10. İNFÜZE EDİLEN CD34+ VE CD3+ HÜCRE MİKTARININ VE CD34+/CD3+ ORANININ AKHN SONUÇLARINA ETKİLERİ

ŞEN T., KILIÇ Ö., ŞAHİN U., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

11. KRONİK MİYELOİD LÖSEMİDE DERİN MOLEKÜLER YANIT SONRASI TEDAVİSİZ İZLEM; TEK MERKEZE AİT KLİNİK SONUÇLARIN DEĞERLENDİRİLMESİ

HANEDAR E., CENGİZ SEVAL G., ŞAHİN U., AKBULUT M. H., TOPÇUOĞLU P., BEKSAÇ M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

12. HOW HAVE NOVEL QUADRUPLET AND TRIPLET FRONT-LINE OPTIONS CHANGED THE TREATMENT LANDSCAPE FOR EARLY RELAPSED/REFRACTORY MULTIPLE MYELOMA

CENGİZ SEVAL G.

Haematology Academy 2024, 15 - 16 November 2024, (Full Text)

13. An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Ludwig H., Dimopoulos M. A., BEKSAÇ M., Bridoux F., CENGİZ SEVAL G., Arcaini L., et al.

66th ASH Annual Meeting, 07 December 2024, (Full Text)

14. Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Zamagni E., Silzle T., Špička I., Tahri S., Lonergan S., Nijhof I. S., et al.

66th ASH Annual Meeting, 07 December 2024, (Full Text)

15. Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)

Ailawadhi S., Gavriatopoulou M., Peterson J., Ntanasis-Stathopoulos I., El-Haddad G., Grajales-Cruz A., et al.

66th ASH Annual Meeting, 07 December 2024, (Full Text)

16. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

Yüksel M., Cengiz Seval G., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T.

50.Ulusal Hematoloji Kongresi, Antalya, Turkey, 29 October - 02 November 2024, pp.136-137, (Full Text)

17. NÜKS/DİRENÇLİ MULTİPL MYELOM’DA ELRANATAMAB TÜRKİYE DENEYİMİ: İLK SONUÇLAR

Salihoğlu A., Cengiz Seval G., Uzay A., Yüksel M., Beşışık S., Özsan G. H.

50.Ulusal Hematoloji Kongresi, Antalya, Turkey, 29 October - 02 November 2024, pp.156-157, (Full Text)

18. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

Yüksel M., Şanlı H., Dalva K., Cengiz Seval G., Topçuoğlu P., Arslan Ö., et al.

50.Ulusal Hematoloji Kongresi, Antalya, Turkey, 29 October - 02 November 2024, pp.111, (Full Text)

19. HİPEREOZİNOFİLİK SENDROM ALT TİPLERİNDE TANI VE TEDAVİ: RETROSPEKTİF TEK MERKEZLİ ÇALIŞMA

BEKTAŞ M., ÇİFTÇİ A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

20. STEROİD REFRAKTER GRAFT VERSUS HOST HASTALIĞINDA FOTOFEREZ KULLANIMI VE YANITLARININ DEĞERLENDİRİLMESİ, TEK MERKEZ DENEYİMİ

BEKTAŞ M., ÇİFTÇİ A., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

21. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

YÜKSEL M., DEMİR C. K., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

50.Ulusal Hematoloji Kongresi, 29 October 2024, (Full Text)

22. GÜNCEL KLAVUZLAR EŞLİĞİNDE KLİNİKTE MASTOSİTOZ: TEK MERKEZ DENEYİMİ

AYDOĞAN M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

23. NÜKS DİRENÇLİ T HÜCRELİ LENFOMALARDA PRALATREKSAT KULLANIMI: TEK MERKEZ DENEYİMİ

SÖNMEZ G. M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

24. DİRENÇLİ BİR HEMORAJİK SİSTİK VAKASI

ŞEN T., KILIÇ Ö., SÖNMEZ G. M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., et al.

50.Ulusal Hematoloji Kongresi, 29 October 2024, (Full Text)

25. MANTLE HÜCRELİ LENFOMA TANILI HASTALARDA İBRUTİNİB KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., CENGİZ SEVAL G., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

26. PAROKSİSMAL NOKTURNAL HEMOGLOBİNÜRİ TANILI HASTALARIN DEĞERLENDİRMESİ, TEK MERKEZLİ ÇALIŞMA

BEKTAŞ M., ÇİFTÇİ A., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

27. Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaMTM)

Ailawadhi S., Gavriatopoulou M., Peterson J., Ntanasis-Stathopoulos I., El-Haddad G., Grajales-Cruz A., et al.

66th Annual Meeting of the American-Society-of-Hematology (ASH), Florida, United States Of America, 6 - 09 December 2025, vol.144, pp.862-863, (Summary Text) Sustainable Development

28. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

SÖNMEZ G. M., ÖZSAN İ., DÜZ B., ŞANLI H., CENGİZ SEVAL G., DALVA K., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

29. PHENOTYPES OF BONE MARROW MONOCYTES IN HEMATOPOİETİC CELL TRANSPLANTATION FOR ACUTE MYELOİD LEUKEMIA: A DESCRIPTIVE PILOT STUDY

YAVUZ ERMİŞ G., DALVA K., KIRCALI E., İPEK Ş., OKUL N., CENGİZ SEVAL G., et al.

11TH AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, 19 - 22 September 2024, (Full Text)

30. Prognostic evaluation of PET/CT in residual post-chemotherapy +/- RT masses in patients with Hodgkin Lymphoma and its impact on survival

BEKTAŞ M., KAR İ., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., et al.

11TH AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, 19 - 22 September 2024, (Full Text)

31. Extramedullary disease

CENGİZ SEVAL G.

EMN Annual Meeting, 18 - 20 April 2024, (Full Text)

32. İKİ ULUSLARARASI MİYELOM EVRELEME SİSTEMİNİN (ISS’NİN İKİNCİ REVİZYONU R2-ISS VE MAYO EKLENEN EVRELEME SİSTEMİ (MASS)) ANKARA TIP HEMATOLOJİ VERİLERİNDE VALİDASYONU

Cengiz Seval G., Aydoğan M., Akbulut M. H., Karakaya B., Yavuz G., Yılmaz H., et al.

49. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 05 November 2023, pp.1-392, (Full Text)

33. KRONİK LENFOSİTİK LÖSEMİLERDE İMMUNGLOBULİN GENLERİ VARYANT ALT TİPLERİ, ALT KLONLAR İLE SOMATİK HİPERMUTASYON İLE HASTALIK BİYOLOJİSİNİN İLİŞKİSİ

Aygün R. Ş., Yüksel S., Örüncü M. B., Yüksel M., Cengiz Seval G., Arslan Ö., et al.

49. Ulusal Hematoloji Kongresi , Antalya, Turkey, 1 - 05 November 2023, pp.148-149, (Full Text)

34. THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML

Aydogan M., Karakaya B., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.181-182, (Summary Text)

35. Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Koyun D., ŞAHİN U., CENGİZ SEVAL G., Sahin D. G., Gokmen A., Bozdag S. C., et al.

65th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 9 - 12 December 2023, vol.142, (Summary Text)

36. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

Karakaya B., Yilmaz H., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.457-458, (Summary Text)

37. ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.301-302, (Summary Text)

38. EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

Beksaç M., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, France, 23 April 2023, vol.58, pp.107, (Full Text)

39. P19 EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

BEKSAÇ M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation, France, 23 April 2023, (Full Text)

40. Comparison of C-11 methionine and F-18 FDG PET/CT findings in evaluation of multiple myeloma: first Turkey Experience

ÖZKAN E., DEMİR B., CENGİZ SEVAL G., ARAZ M., SOYDAL Ç., BEKSAÇ M., et al.

Annuals Congress of the European Association of Nuclear Medicine, 9 - 13 September 2023, (Full Text)

41. ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA:A MULTICENTER REAL WORLD EXPERIENCE

Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Civriz Bozdağ S., Koçak Toprak S., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 12 - 13 May 2023, pp.40-41, (Full Text)

42. Multiple myelomada hastalık değerlendirilmesinde C-11 Metiyonin PET/BT deneyimi

ÖZKAN E., DEMİR B., CENGİZ SEVAL G., ARAZ M., SOYDAL Ç., BEKSAÇ M., et al.

35.Ulusal Nükleer Tıp Kongresi, 26 April 2023, (Full Text)

43. Multiple myelomada hastaık değerlendirilmesinde C-11 Metiyonin PET/BT deneyimi

ÖZKAN E., DEMİR B., CENGİZ SEVAL G., ARAZ M., SOYDAL Ç., BEKSAÇ M., et al.

35.Ulusal Nükleer Tıp Kongresi, 26 April 2023, (Full Text)

44. AKUT MİYELOİD LÖSEMİ HASTALARININ 2022 ELN GENETİK RİSK SINIFLANDIRMASI İLE VALİDASYONU: THD-AML HASTA KAYIT ÇALIŞMASI

PINAR İ. E., KARATAŞ A. F., ÇELİK S., POLAT M. G., ILTAR U., CENGİZ SEVAL G., et al.

15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 16 - 19 March 2023, (Summary Text)

45. COVID-19 ENFEKSİYONUNUN OTOLOG KÖK HÜCRE NAKLİ UYGULANAN MULTİPLE MYELOM TANILI BİR OLGUDA ETKİSİ

Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Beksaç M., Koçak Toprak S.

15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi , Antalya, Turkey, 16 - 19 March 2023, pp.101, (Full Text)

46. INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE

YİLMAZ H., İLKEM ŞAHİN Y., MAMMADLİ H., YILDIZ B., DURAN O. F., AYDIN R. F., et al.

9th International Congress on Leukemia Lymphoma Myeloma, 12 May 2023, (Full Text)

47. INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE

YİLMAZ H., ŞAHİN Y. İ., MAMMADLİ H., YILDIZ B., DURAN O. F., AYDIN R. F., et al.

9th International Congress on Leukemia Lymphoma Myeloma, 12 May 2023, (Full Text)

48. THE LDH LEVEL AFTER THE INFUSION OF FRESH OR CRYOPRESERVED HEMATOPOIETIC PROGENITOR CELLS HAVE NO IMPACT ON THE OUTCOME

Sönmez G. M., Conger N., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., BEKSAÇ M., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Turkey, 12 May 2023, (Full Text)

49. INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE

YILMAZ H., Şahin Y. I., Mammadli H., YILDIZ B., Duran O. F., AYDIN R. F., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Turkey, 12 May 2023, (Full Text)

50. Phosphatidylserine (PS) and Tyro3-Axl-Mertk (TAM) Receptor Tyrosine Kinase (RTK) Levels Detection and Exosomes Surface in Chronic Lymphocyctic Leukemia (CLL)

Bay M., Cengiz Seval G., Coşkun Ö., Gürman G., Özsoy Erdaş N.

International Congress of Health Research , Ankara, Turkey, 8 - 09 December 2022, pp.33-34, (Summary Text)

51. Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti- CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Yılmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydoğan M., Civriz Bozdağ S., et al.

64th ASH Annual Meeting & Exposition, Louisiana, United States Of America, 09 December 2022, (Full Text)

52. Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

BEKSAÇ M., TUĞLULAR A. T., GAY F., MİNA R., Katodritou E., ÜNAL A., et al.

64th ASH Annual Meeting & Exposition, United States Of America, 9 - 12 December 2022, (Full Text)

53. NÜKS VE DİRENÇLİ HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: ÇOK MERKEZLİ GERÇEK YAŞAM VERİSİ

Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Gökmen A., Civriz Bozdağ S., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 November 2022, pp.130-132, (Full Text)

54. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

İLHAN ., Yavuz G., CENGİZ SEVAL G., Bozdag S. C., YÜKSEL M., TOPÇUOĞLU P., et al.

48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Czech Republic, 19 - 23 March 2022, vol.57, pp.125, (Summary Text)

55. The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.12673-12674, (Summary Text)

56. Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Yilmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydogan M., Bozdag S. C., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.4369-4370, (Summary Text)

57. Relaps/Refrakter Mikozis Fungoides ve Sezary Sendromu Vakalarında Brentiksumab Vedotinin Etkinliği: Tek Merkez Deneyimi

CENGİZ SEVAL G., ŞANLI H., GÜNDÜZ K., CİVRİZ BOZDAĞ S., AKAY B. N., YILDIZHAN İ., et al.

30. Ulusal Dermatoloji Kongresi, Girne, Cyprus (Kktc), 18 - 22 October 2022, (Summary Text)

58. IS IT SAFE TO PERFORM OVARIAN CRYOPRESERVATION AND TRANSPLANTATION IN PATIENTS WITH LEUKEMIA A 5-YEAR SURVIVAL ANALYSIS DATA

Sönmezer M., Şükür Y. E., Saeinti K. G., Ozkavukcu S., Kankaya D., Cengiz Seval G., et al.

78th Annual Scientific Congress and Expo of the American-Society-for-Reproductive-Medicine (ASRM), California, United States Of America, 22 - 26 October 2022, (Summary Text)

59. Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

CENGİZ SEVAL G., KUZU I., Yüksel S., YILMAZ H., Yavuz G., KAYGUSUZ G., et al.

19th International Myeloma Society Annual Meeting, 25 August 2022, (Full Text)

60. Ibrutınıb As A Promısıng Treatment For Waldenström Macroglobulınemıa

İLHAN O., CENGİZ SEVAL G., AVCU F., Ferhanoglu B., ÖZCAN M., ÇETİN G., et al.

HemaSphere 2022, United States Of America, 05 June 2022, (Full Text)

61. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation

TOPRAK S. K., KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

2022 ASCO Annual Meeting, United States Of America, 01 June 2022, (Full Text)

62. Response And Vaccınatıon Status Or Lack Of Immunoparesıs Are Assocıated Wıth Better Outcome Followıng Covıd-19 Infectıon Among Patıents Dıagnosed Wıth Multıple Myeloma: A Sıngle Center Experıence On 110 Patıents

CENGİZ SEVAL G., KIRCALİ E., KOYUN D., KARAKAYA B., YILMAZ H., AKBULUT H., et al.

3rd European Myeloma Network Meeting Virtual, United States Of America, 06 April 2022, (Full Text)

63. Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), United States Of America, 19 - 22 March 2022, (Full Text)

64. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

İLHAN O., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), United States Of America, 19 - 22 March 2022, (Full Text)

65. QUANTIFICATION OF MRD AT 10-5 BY FLOW IN THE STEM CELL GRAFT CORRELATES WITH MARROW MRD AND PFS FOLLOWING AHCT AMONG PATIENTS DIAGNOSED WITH MM

CENGİZ SEVAL G., DALVA K., ÖZ M. D., GÜRMAN G., İLHAN O., BEKSAÇ M.

48th Annual Meeting of the EBMT, 19 March 2022, (Full Text)

66. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022, (Full Text)

67. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI NÜKS ETMİŞ AML HASTALARINDA HİPOMETİLE EDİCİ İLAÇLARLA KOMBİNE VENETOKLAX TEDAVİSİ

ÖZTÜRK C., URAL A. U., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022, (Full Text)

68. GRAFT VERSUS HOST HASTALIĞI PROFİLAKSİSİNDE ATG VE POST CY KULLANIMININ NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

Karakaya B., ŞAHİN Y. İ., MAMMADLI H., Yavuz G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022, (Full Text)

69. THE OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN LYPHOMA

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63TH ASH CONGRESS, ATLANTA, United States Of America, 8 - 11 December 2021, (Full Text)

70. Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

CENGİZ SEVAL G., DALVA K., ÖZ D., BAKANAY S., SOYDAN E., GÜRMAN G., et al.

63rd ASH Annual Meeting and Exposition, United States Of America, 11 December 2021, (Full Text)

71. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63rd ASH Annual Meeting and Exposition, 11 December 2021, (Full Text)

72. Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic

BEKSAÇ M., TUĞLULAR T., ÜNAL A., Cavo M., Gay F., KATODRITOU E., et al.

63rd ASH Annual Meeting and Exposition, United States Of America, 11 - 13 December 2021, (Full Text)

73. Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association

Jöris M., Bernas S., H. Schmidt A., Feinberg J., Sacchi N., Elmoazzen H., et al.

63rd ASH Annual Meeting and Exposition, 11 December 2021, (Full Text)

74. PROFLAKTİK DEFİBROTİD SOS DIŞINDA AKUT GRAFT VS HOST HASTALIĞINDA DA ETKİN

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

47. Ulusal Hematoloji Kongresi, 04 November 2021, (Full Text)

75. Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

AKIN H., CENGİZ SEVAL G., ATİLLA P., YURDAKUL MESUTOĞLU P., TANER O., ALNIAÇIK R., et al.

18th International Myeloma Workshop, United States Of America, 8 - 11 September 2021, (Full Text)

76. Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

CENGİZ SEVAL G., DALVA K., ÖZ M. D., ÖZTÜRK S., SOYDAN E., GÜRMAN G., et al.

18th International Myeloma Workshop, United States Of America, 8 - 11 September 2021, (Full Text)

77. A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance

BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., et al.

23rd Congress of the European Hematology Association, 2021, 14 June 2018, pp.249, (Full Text)

78. DETERMINATION OF INFECTION FREQUENCY IN PATIENTS USING RUXOLITINIB DUE TO GRAFT VERSUS HOST DISEASE

YİLMAZ H., KIRCALI E., ÖZTÜRK C., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Turkey, 21 - 22 May 2021, (Full Text)

79. Postinduction FDG-PET imaging improves the impact of biochemical response assessment on transplant outcome.

Cengiz Seval G., Özkan E., Araz M., Kırcalı E., Koyun D., Gürman G., et al.

8th International Congress on Leukemia Lymphoma Myeloma, 2021, İstanbul, Turkey, 21 May 2021, vol.38, pp.45, (Full Text)

80. Killer Immunoglobulin-like Haplotype BB is Observed More Frequently Among Myeloma Cases Compared to Healthy Controls

AKIN H. Y., ATACA ATİLLA P., YURDAKUL MESUTOĞLU P., CENGİZ SEVAL G., OTLU T., ALNIAÇIK R., et al.

8th International Congress Leukemia Lymphoma Myeloma (ICLLM), 21 - 22 May 2021, (Full Text)

81. MELFELAN HAZIRLIK REJİMİ TEK GÜN VE İKİ GÜN KULLANIMI YAN ETKİ DEĞERLENDİRMESİ, FARK VAR MI ?

ÖZTÜRK N., BEKLER İ., ERDEMSOY B., ŞEN T., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

82. ALLOJENİK KÖK HÜCRE NAKLİ HASTALARINDA PERİTRANSPLANT METRONİDAZOL KULLANIMIYLA AKUT GVHD RİSKİNİN İLİŞKİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

83. MELFALAN JENERİKLERİ ARASINDAKİ TİFİLİT YAN ETKİ SIKLIĞININ KARŞILAŞTIRILMASI

ÖZTÜRK N., YILMAZ H., ALKAN TEKEŞ İ., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

84. MULTİPL MİYELOMDA OTOLOG PRİFERİK KÖK HÜCRE NAKLİ SONRASI ERKEN NÜKSÜ BELİRLEMEDE CIBMTR, ISS VE R-ISS SKORLAMA SİSTEMLERİNİN KARŞILAŞTIRILMASI

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

85. Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi?

YÜKSEL M., CENGİZ SEVAL G., DALVA K., CEYLAN G., AKAL F., CİVRİZ BOZDAĞ S., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 April 2021, (Full Text)

86. KAN GRUBU UYUŞUMSUZLUĞUNUN HAPLOİDENTİK TRANSPLANT SONUÇLARINA ETKİSİ VE KAN GRUBU DÖNÜŞÜM SÜRECİ

GÖKGÖZ M., ŞAHİN U., GÖKMEN A., SOYDAN E., CENGİZ SEVAL G., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

87. THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., Yavuz G., et al.

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.38, no.71, pp.1-81, (Full Text)

88. PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION

KIRCALI E., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.38, pp.50, (Full Text) Sustainable Development

89. PRIMARY GASTRIC NK/T CELL LYMPHOMA WITH T CELL PHENOTYPE: A RARE EBV RELATED LOCALLY INVOLVED AGRESSIVE LYMPHOMA CASE.

KOYUN D., YÜKSEL S., CENGİZ SEVAL G., KUZU I., ÖZCAN M., CİVRİZ BOZDAĞ S.

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.28, pp.60-61, (Full Text)

90. The impact of pretransplant ımmunomodulatory drugs on cmv reactıvatıon

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., et al.

8th International congress on leukemia lymphoma myeloma, 2021, 21 May 2021, (Full Text)

91. Phenotypes of Boone Marrow Monocytes in Stem Cell Transplantatio for acute leukemia: A descriptive pilot study

YÜKSEL M., KIRCALI E., ÖZTÜRK C., YİLMAZ H., KOYUN D., ŞENAY İ., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Turkey, 21 May 2021, (Full Text)

92. Is It Safe to Continue Allogeneic Hematopoietic Cell Transplantation Via Cryopreservation during COVID-19 Pandemic?

KIRCALI E., Yavuz G., ÖZTÜRK C., YILMAZ H., CENGİZ SEVAL G., YILDIRIM Y., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2021, 08 February 2021, (Full Text)

93. Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

KIRCALI E., CENGİZ SEVAL G., ÇOLAK S., GÜNDÜZ M., ATACA ATİLLA P., ATİLLA E., et al.

62nd ASH Annual Meeting and Exposition, 05 December 2020, (Full Text)

94. Case Presentation

CENGİZ SEVAL G.

Symposium on Multiple Myeloma and other plasma cell neoplasms, 26 - 28 November 2020, (Full Text)

95. Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

CENGİZ SEVAL G., İLHAN O., FERHANOĞLU A. B., ÇETİN G., KURTOĞLU E., ATALAY F., et al.

62th ASH Annual Meeting, United States Of America, 2 - 11 December 2020, (Full Text)

96. MM HASTALARINDA TANI SIRASINDA, TEDAVİ SONRASINDA IL-10, VEGF DÜZEYLERİ VE KEMİK İLİĞİNDEKİ PARAMETRELERLE İLİŞKİSİ

CENGİZ SEVAL G., DALVA K., TOPRAK S. K., MEMİŞ F.

42. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Full Text)

97. AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

42.Ulusal Hematoloji Kongresi, Turkey, 28 - 30 October 2020, (Full Text)

98. R/ R MULTİPL MYELOM HASTALARINDA BENDAMUSTİN ETKİSİNİN GERİYE YÖNELİK DEĞERLENDİRİLMESİ VE MELFLUFENLE KIYASI

CENGİZ SEVAL G., ÖZCAN M., BEKSAÇ M., ATİLLA E., ATACA ATİLLA P.

42.Ulusal Hematoloji Kongresi, Turkey, 28 - 30 October 2020, (Full Text)

99. Foliküler lenfomada bazal PET'te toplam metabolik tümör hacmi ve toplan lezyon glikolizinin prognostik önemi.

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., ÖZKAN E., et al.

46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Full Text)

100. KÖK HÜCRE ÜRÜNÜNDEKİ CD34 HÜCRE ALT GRUPLARI VE ENGRAFMAN İLE İLİŞKİSİ

CENGİZ SEVAL G., TOPÇUOĞLU P., DALVA K., İLHAN O., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.

46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Full Text)

101. Hematolojik Hastalıklarda Covıd-19 Sıklığı ve Seyri-Çok Merkezli Kayıt Çalışması

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., BEKSAÇ M., TOPÇUOĞLU P., YÜKSEL M.

46.Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Full Text)

102. APLASTİK ANEMİ İLE BİRLİKTELİĞİ OLAN VE OLMAYAN PNHHASTALARINDA ALLOJENEİK KÖK HÜCRE NAKLİ DENEYİMİ

YILMAZ A. F., SOYER N., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ÜNAL A., et al.

46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, pp.86, (Summary Text)

103. A New Hope in the Treatment of steroid-refractory Graft Versus Host Disease (Sr-GVHD) after Allogeneic Hematopoetic Stem Cell Transplantation (AHSCT): Ruxolitinib

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., DEVECİ B., PEHLİVAN M., KAYNAR L., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 August 2020, (Full Text)

104. CD34+ Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

ERTEPE G., İPEK Ş., YILDIRIM Y., GÖZÜKARA M. G., DALVA K., CENGİZ SEVAL G., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 August 2020, (Full Text)

105. The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALİ E., BALTACI M. A., TOPÇUOĞLU P., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020, (Full Text)

106. Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa?

CENGİZ SEVAL G., EKİN K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020, (Full Text)

107. Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag

KIRCALİ E., CENGİZ SEVAL G., KOYUN D., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020, (Full Text)

108. Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML)

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT, 29 August - 01 September 2020, (Full Text)

109. Diagnosis and follow up of myeloma patients

CENGİZ SEVAL G.

International Myeloma Society, 24 - 25 July 2020, (Full Text)

110. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, Milan, Italy, 11 May - 13 February 2020, vol.22, pp.35, (Summary Text)

111. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kırcali E., Öztürk C., et al.

ASCO 2020, 29 May - 02 June 2020, vol.38, no.15, (Full Text)

112. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL M., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, 11 - 13 May 2020, (Full Text)

113. Hematolojik malignitelerde nakil sonrası hematogon değerlerinin prognoza etkisi var mıdır?

CENGİZ SEVAL G., DALVA K., TOPRAK S. K.

12.Ulusal Kemik iliği transplantasyonu ve hücresel tedaviler kongresi, Turkey, 5 - 07 March 2020, (Full Text)

114. CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

115. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

116. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

117. AKRABA DIŞI VERİCİDEN KHN SÜRECİ BİLEŞENLERİNİN NAKİL ZAMANLAMASINA ETKİSİ: NAKİL ZAMANI DAHA ERKENE ÇEKİLEBİLİR Mİ?

CENGİZ SEVAL G., TOPÇUOĞLU P., BEKSAÇ M., YÜKSEL M., GÜRMAN G., DALVA K., et al.

12.Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

118. YÜKSEK DOZ MELFALAN SONRASI YANIT DERİNLİĞİ ARTIŞI NÖTROPENİ DERİNLİĞİ İLEDEĞİL AMA TROMBOSİTOPENİ DERİNLİĞİ İLE İLŞKİLİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

119. Ibrutinib As a Promising Treatment for Pulmonary Complications Due to Refractory Chronic Graft Versus Host Disease

İLHAN O., CENGİZ SEVAL G., Uzay A., KAYA E., Ozturk Z. N., Deveci B., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, United States Of America, 19 - 23 February 2020, vol.26, (Summary Text)

120. KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells

Akin H. Y., Turasan E., Kircali E., AKKUŞ E., CENGİZ SEVAL G., Yurdakul-Mesutoglu P., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, United States Of America, 19 - 23 February 2020, vol.26, (Summary Text)

121. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2020, 19 - 23 February 2020, (Full Text)

122. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow

CENGİZ SEVAL G., USLU A., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 February 2020, (Full Text)

123. A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R)

Beksaç M., Cengiz Seval G., Koyun D., Topçuoğlu P., Yüksel M., Gürman G., et al.

AMERICAN JOURNAL OF HEMATOLOGY, 1 - 05 November 2019, (Full Text)

124. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., Ozturk N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

125. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

126. Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

CENGİZ SEVAL G., KUZU I., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

127. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Kircali E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

128. YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019, (Summary Text)

129. HANGİSİ, ORJİNAL İMATİNİB Mİ JENERİK Mİ KRONİK MYELOİD LÖSEMİDE DAHA ETKİN?

KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

45. Ulusal Hematoloji Kongresi, 31 October 2019, (Full Text)

130. NGS TUM SECENEKLERİ TUKETMİŞ NUKS VE DİRENCLİ MMHASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADAREHBERLİK EDEBİLİR Mİ?

CENGİZ SEVAL G., KUZU I., YÜKSEL S., DALVA K., ÖZCAN M., BEKSAÇ M.

45. Ulusal Hematoloji Kongresi, Turkey, 31 October - 02 November 2019, (Summary Text)

131. KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019, (Summary Text)

132. IMID/PI İÇEREN TEDAVİLERE DİRENÇLİ MM OLGULARINDA POM/LEN İLE BİRLİKTE ELOTUZUMAB TEDAVİSİ KALICI ≥ÇİKY SAĞLAYABİLİR Mİ?

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., FIRATLI TUĞLULAR T., ARSLAN Ö., GÖKER H., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Turkey, 30 October 2019, pp.168, (Full Text)

133. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 52 patients

CENGİZ SEVAL G., Topcuoglu P., Arslan O., GÜRMAN G., Demirer T., Kuzu I., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30, pp.441, (Summary Text) Sustainable Development

134. Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

17th International Myeloma Workshop, 12 - 15 September 2019, (Full Text)

135. Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., TUĞLULAR A. T., ARSLAN Ö., GÖKER A. H., et al.

17th International Myeloma Workshop, 12 - 15 September 2019, (Summary Text)

136. Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

YÜKSEL M., CENGİZ SEVAL G., Uslu A., Kircili E., KOYUN D., Ozturk C., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.505-506, (Summary Text)

137. Is mobilization with chemotherapy effect response in the multiple myeloma?

CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.500, (Summary Text)

138. Results of a single center experience: An attempt to augment conditioning regimen in first autologous stem cell transplantation

CENGİZ SEVAL G., KOYUN D., Kircali E., TOPRAK S. K., ÖZCAN M., BEKSAÇ M.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.500-501, (Summary Text)

139. Blood group incompatibility in haplo-identical stem cell transplantation: Favor or unfavorable effect on the erythrocyte recovery?

CENGİZ SEVAL G., Uslu A., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.368-369, (Summary Text)

140. Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

İLHAN O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.382, (Summary Text)

141. Clonal plasma cell detection by high sensitive flow cytometry in aphaeresis product is poor prognostic and not increased by use of plerixafor alone

CENGİZ SEVAL G., Uslu A., DALVA K., Bakanay S. M., Merter M., Sahin U., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.496-497, (Summary Text)

142. Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ?

YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

24 Congress of the European Hematology Association, 13 - 16 June 2019, (Summary Text)

143. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

144. The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence

DALVA K., CENGİZ SEVAL G., OZ d., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

HLA, 01 May 2019, vol.93, pp.368-369, (Full Text)

145. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

146. retrospective analysis of 149 unselected patıents wıth mantle cell lymphoma confırms prognostic relevance of mıpı: sıngle center ecperıence

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

ICLLM 2019, 02 May 2019, (Full Text)

147. CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

Yüksel M., Kırcalı E., Cengiz Seval G., Koyun D., Uslu A., Öztürk C., et al.

7th International Congress on Leukemia Lymphoma, İstanbul, Turkey, 2 - 04 May 2019, (Full Text)

148. MULTİPL MİYELOMDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: KİME NE ZAMAN?

CENGİZ SEVAL G.

1. Ulusal Miyelom Uzmanlar Sempozyumu, 08 March 2019, (Full Text)

149. Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları

Cengiz Seval G., Koyun D., Kırcali E., Şahin U., Toprak S. K., Özcan M., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2019, (Full Text)

150. Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi?

CENGİZ SEVAL G., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

151. Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler mi?

CENGİZ SEVAL G., USLU A., DALVA K., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

152. Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması

CENGİZ SEVAL G., ULAŞ B. B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

153. Posttransplant Lenfositoz Önemli Bir Parametre midir?

CENGİZ SEVAL G., USLU A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

154. T-All Hastalarında Allojeneik Hematopoetik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?

CENGİZ SEVAL G., USLU A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

155. Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz

Kırcali E., Cengiz Seval G., Koyun D., Civriz Bozdağ S., Topçuoğlu P., Özcan M., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2019, (Full Text)

156. Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi?

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALİ E., KOYUN D., ÖZTÜRK C., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

157. Akut Miyeloid Lösemide Nakil Öncesi Minimal Kalıntı Hastalık Diğer Risk Faktörlerinden Daha Önemli midir

NARLI ÖZDEMİR Z., ŞAHİN U., BALTACI M. A., USLU A., ÖZTÜRK C., CENGİZ SEVAL G., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

158. MİYELOM HASTALARINDA OHKHN ÖNCESİ KULLANILANİLAÇLARIN CMV REAKTİVASYONU ÜZERİNE SAĞKALIMIAZALTICI ETKİSİ OLABİLİR Mİ?

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

159. TREKEAL BASI VE NEFES DARLIĞI İLE PREZENTE OLAN BÜYÜK MEDİASTİNAL KİTLESİ BULUNAN EKSTRAMEDÜLLER MULTİPLE MYELOM

USLU A., CENGİZ SEVAL G., ÖZTÜRK C., NARLI ÖZDEMİR Z., YÜKSEL M.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2019, (Summary Text)

160. CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019, (Full Text)

161. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

CENGİZ SEVAL G., Atilla E., Ulas B., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., et al.

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, United States Of America, 13 - 24 February 2019, vol.25, (Summary Text)

162. HAPLOİDENTİK KÖK HÜCRE NAKİLLERİNDE KAN GRUBU UYUMSUZLUĞU: ERİTROSİT ENGRAFTMANI ÜZERİNE ETKİSİ VAR MI?

CENGİZ SEVAL G., USLU A., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 March 2019, (Full Text)

163. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019, (Full Text)

164. PRİMER İMMUN YETMEZLİKLİ ERİŞKİN HASTALARDA ALLOJENEİK NAKİL DENEYİMİ

YÜKSEL M., NARLI ÖZDEMİR Z., ARDENİZ F. Ö., ÇAĞDAŞ AYVAZ D., ALTINTAŞ N. D., ÖZDEMİR KUMBASAR Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2019, (Summary Text)

165. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Cente Institution Experience

TOPÇUOĞLU P., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., et al.

60th ASH Annual Meeting and Exposition, 01 December 2018, (Full Text)

166. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

GÜRMAN G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132, (Summary Text)

167. Residual Clonal Plasma Cells Detected By Flow Cytometry at 10(-4)level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

CENGİZ SEVAL G., DALVA K., BAKANAY ÖZTÜRK Ş. M., Merter M., Sahin U., Uslu A., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132, (Summary Text)

168. Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

İLHAN O., CENGİZ SEVAL G., ÖZKURT Z. N., Ural A. U., Ayli M., Sevindik O. G., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132, (Summary Text)

169. Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience

CENGİZ SEVAL G., Ulas B., TAŞCI O., Ozel F., Bulat B., KUZU I., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132, (Summary Text)

170. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ

KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018, (Full Text)

171. İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir

CENGİZ SEVAL G., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., USLU A., NARLI ÖZDEMİR Z., et al.

44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2018, (Summary Text)

172. Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi

DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., et al.

44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2018, pp.245-246, (Summary Text)

173. BLASTİK PLAZMASİTOİD DENDRİTİK HÜCRELİ NEOPLAZİ: NADİR GÖRÜLEN BİR HEMATOLOJİK MALİGNİTEDE TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October 2018, (Summary Text)

174. STEROİD REFRAKTER KRONİK GRAFT VERSUS HOST HASTALIĞINDA İBRUTİNİB ÇÖZÜM OLABİLİR Mİ?: TÜRKİYE DENEYİMİ

İLHAN O., CENGİZ SEVAL G., GÜLBAŞ Z., ÖZKURT Z. N., URAL A. U., BEKÖZ H. S., et al.

44. Ulusal Hematoloji Kongresi, 31 October 2018, (Full Text)

175. AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUNNAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018, (Summary Text)

176. Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients

CENGİZ SEVAL G., GÖREN ŞAHİN D., SOYDAN E., ÖZÇELİK E. T., GÖKMEN A., GÖKGÖZ Z., et al.

2018 Society of Hematologic Oncology (SOHO) Annual Conference, 12 - 15 September 2018, (Full Text)

177. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

CENGİZ SEVAL G., Sertesen E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., Aslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.338, (Summary Text) Sustainable Development

178. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation

Uslu A., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., GÜRMAN G., Demirer T., Arslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.161-162, (Summary Text)

179. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

Ilhan O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.272-273, (Summary Text)

180. Ruxolitinib in steroid refractory GVHD treatment: single center experience

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Topcuoglu P., Beksac M.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.448-449, (Summary Text)

181. Is post-transplant albumin a predictor of early transplant complications?

TOPÇUOĞLU P., CENGİZ SEVAL G., AKKUŞ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.344-345, (Summary Text)

182. A prospective analysis on the frequency and predictive value of minimal residual disease asessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance

BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., et al.

23rd Congress of European Hematology Association, 14 - 17 June 2018, (Summary Text)

183. Kronik miyeloid lösemi tedavisinde kullanılan bir tirozin kinaz inhibitörü olan nilotinib hücre proliferasyonunu azaltarak ve apoptozu arttırarak gonadotoksik etki gösterir .

KUŞCU N., ÇELİK ÖZENCİ Ç., ÖZKAVUKCU İ. S., CENGİZ SEVAL G., adıgüzel d.

14. Ulusal Histoloji ve Embriyoloji Kongresi, Turkey, 10 - 13 May 2018, (Summary Text)

184. A REAL WORLD MULTICENTER RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: COMPARISON OF PARAOSSEOUS AND SOFT TISSUE PLASMACYTOMAS

Beksac M., Kanellias N., Rosinol L., CENGİZ SEVAL G., Ozet G., Goranova-Marinova V., et al.

1st Meeting of the European-Myeloma-Network, Turin, Italy, 19 - 21 April 2018, vol.103, pp.42-43, (Summary Text)

185. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Blood and Marrow Transplantion Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, United States Of America, 21 - 25 February 2018, vol.24, (Summary Text)

186. KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 March 2018, (Full Text)

187. AKUT GRAFT VERSUS HOST HASTALIĞI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2018, (Summary Text)

188. MYELOFİBROZİSTE ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONUÇLARI: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 March 2018, (Full Text)

189. ITK Gen Defektine Bağlı CD4+ T Hücre Yetmezliği Olan Erişkinde Allojeneik Hematopoietik Kök Hücre Naklinin Sonuçları

YÜKSEL M., NARLI ÖZDEMİR Z., ŞAHİN U., CENGİZ SEVAL G., ÇAĞDAŞ AYVAZ D., ATİKCAN D. T., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2018, pp.138, (Summary Text)

190. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., Topcuoglu P., Ozel F., CİVRİZ BOZDAĞ S., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130, (Summary Text)

191. Peripheral blood stem cell mobilization and collection from elderly patients (≥65 years) with multiple myeloma: A single center experience

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Arslan O., et al.

43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, France, 26 - 29 March 2017, vol.52, (Summary Text)

192. peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience

seval G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

ebmt 2017, 26 - 29 March 2017, (Summary Text)

193. SERUM CYSTATIN C IN PATİENTS WITH ACUTE LEUKEMIA AND ITS PROGNOSTIC IMPORTANCE

CENGİZ SEVAL G., Candar T., AYLI M., COŞARDERELİOĞLU SEÇER Ç., Demirtaş S., ÖZET G., et al.

6. International Congress on Leukemia Lymphoma Myeloma, 11 - 13 May 2017, (Summary Text)

194. Peripheral blood stem cell mobilization and collection from elderly patients (265 years) with multiple myeloma: A single center experience

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 March 2017, (Full Text)

195. Peripheral Blood Stem Cell Mobilization and collection from elderly patients 65 years with multipl myeloma: A , single center exprience

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

43rd Annual Meeting Of EBMT, 26 - 29 March 2017, (Summary Text)

196. SeyrekbirMalignite Primer Mediastinal Büyük B

ATACA ATİLLA P., ATİLLA E., CENGİZ SEVAL G., PEKCAN G., İLHAN O., ARSLAN Ö., et al.

ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016

197. SEYREK BİR MALİGNİTE: PRİMER MEDİASTİNALBÜYÜK B HÜCRELİ LENFOMA

ATACA ATİLLA P., ATİLLA E., CENGİZ SEVAL G., PEKCAN G., İLHAN O., ARSLAN Ö., et al.

42.Ulusal Hematoloji Kongresi, Turkey, 18 - 22 October 2016, (Summary Text)

198. Immune Reconstitution ofter HLA-Haploidentical and HLA-Matched Allogeneic Transplantation (BMT) Utilizing Posttransplantation Cyclophosphamide

CENGİZ SEVAL G., Vulic A., McCurdy S., Kanakry C., Varadhan R., Symons H., et al.

41st Annual Meeting of the European Society for Blood and Marrow Transplantation, 22 March 2015, (Full Text)

199. The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model

CENGİZ SEVAL G., ÖZKAVUKCU İ. S., SEVAL M. M., Ayli M., ÖZCAN M.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

200. Kronik miyeloid lösemi tedavi dozundaki nilotinib’in folikülogenez ve spermatogenez üzerindeki etkisinin sağlıklı fare modelinde gösterilmesi

CENGİZ SEVAL G., ÖZKAVUKCU İ. S., SEVAL M. M., AYLI M.

40. Ulusal Hematoloji Kongresi, Antalya, Turkey, 22 - 25 October 2014

201. MULTİPLE MYELOMA HASTALARINDA HEMATOPOİETİK KÖK HÜCRE MOBİLİZASYONU SÜRECİNDE YAŞ FAKTÖRÜNÜN ETKİSİ VAR MI?

CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., BAY M., AYYILDIZ E., İLHAN O.

9. Ulusal Aferez Kongresi, 04 September 2014, (Full Text)

202. STEM CELL MOBILIZASTION IN ELDERLY MULTIPLE MYELOMA PATIENTS: SINGLE CENTER EXPERIENCE

TOPRAK S. K., CENGİZ SEVAL G., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

19th Congress of the European Hematology Association, 12 June 2014, (Full Text)

203. STEM CELL MOBILIZATION IN ELDERLY MULTIPLE MYELOMA PATIENTS: SINGLE CENTER EXPERIENCE

TOPRAK S. K., CENGİZ SEVAL G., Ayyildiz E., Topcuoglu P., Arslan O., Ozcan M., et al.

19th Congress of the European-Hematology-Association, Milan, Italy, 12 - 15 June 2014, vol.99, pp.721, (Summary Text)

204. Nilotinib a second generation tyrosine kinase inhibitor does not effect spermatogenesis within chronic myeloid leukemia treatment dose ranges in mouse model

SEVAL G., SEVAL M. M., ÖZKAVUKCU İ. S.

10th Biennial Conference of Alpha, Scientists in reproductive Medicine, Antalya, Turkey, 9 - 11 May 2014

205. OTOLOG HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASINDA GELİŞEN BİR CMV RETİNİT VAKASI

CENGİZ SEVAL G., TOPÇUOĞLU P., İDEMEN C., DEMİRER T.

8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 March 2014, (Summary Text)

206. AKRABA DIŞI ALLOJENEİK HEMATOPOETİK HÜCRE NAKLİNDE HLA UYUŞUMUNUN ETKİSİ-TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., TOPÇUOĞLU P., ÖZEN M., GÜNDÜZ M., ATİLLA E., DALVA K., et al.

8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 March 2014, (Summary Text)

207. Sequential chemotherapy plus allogeneic haematopoetic stem cell transplantation: is it a good alternative as salvage treatment for heavily pretreated patients with leukaemia?

Topcuoglu P., CENGİZ SEVAL G., Arslan O., Ilhan O., Akan H., Beksac M., et al.

39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), London, Canada, 7 - 10 April 2013, vol.48, (Summary Text)

208. BLOOD DONORS AND FACTORS IMPACTING THE BLOOD DONATION DECISION: MOTIVATIONS, BELIEFS AND ATTITUDES

KARACAN E., Aktan Z., CENGİZ SEVAL G., PALABIYIKOĞLU N. R., AYLI M.

14th International Congress of the World Apheresis Association and 7th National Congress of Turkish Society of Apheresis, 13 September 2012, (Full Text)

209. IDENTIFICATION OF RISK FACTORS FOR FIBROSIS PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE

CENGİZ SEVAL G., İDİLMAN R., ÇINAR K., Seven G., Yakut M., Kabacam G., et al.

61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 29 October - 02 November 2010, vol.52, (Summary Text)